A novel extraction and derivatization procedure for the cocaine metabolite benzoylecgonine (BZE) was developed and evaluated for use in a high.volume forensic urine analysis laboratory. Extractions utilized a Speedisk 48 TM positive pressure extraction manifold and polymer.based cation.exchange extraction columns. Samples were derivatized by the addition of pentafluoropropionic anhydride and pentafluoropropanol. All analyses were performed in selected ion monitoring mode; ions included m/z 421,300, 272, 429, and 303 with m/z 421 to 429 ratio used for quantitation. The average extraction efficiency was 80%. Seventy-five common over-the-counter products, including prescription drugs, drug metabolites, and other drugs of abuse, demonstrated no significant interference with respect to chromatography or quantitation. The limit of detection and limit of quantitation were calculated at 12.5 ng/mL, and the assay was linear from 12.5 to 20,000 ng/mL with an r 2 of 0.99932. A series of 20 precision samples (100 ng/mL) produced an average response of 97.8 ng/mL and a percent coefficient of variation of 4.1%. A set of 79 archived human urine samples that had previously been found to contain BZE were analyzed by 3 separate laboratories. The results did not differ significantly from prior quantitation or between laboratories. The Speedisk has proven viable for a high.volume production facility reducing overall cost of analysis by decreasing analysis time and minimizing waste production while meeting strict forensic requirements.
Introduction
Although cocaine use has been steady or declining in recent years, the international trafficking network remains intact and has thwarted numerous attempts to limit importation (1) .
Cocaine is sold on the street at lower cost and higher purity despite the coordinated efforts of law enforcement. Consistent with these trends, cocaine use has been a constant concern.
Forensic urine specimen testing requires initial testing by irnmunoassay followed by confirmation by gas chromatography-mass spectrometry (GC-MS). Currently, our laboratory's initial cocaine screening assay utilizes the Dade-Behring Emit II TM cocaine metabolite immunoassay. The benzoylecgonine (BZE) confirmation test is based on GC-MS operated in the selected ion monitoring (SIM) mode.
For BZE confirmation testing, several extraction methods have been investigated, including liquid-liquid and automated solid-phase extraction (SPE) techniques (2-7). For several years, this laboratory has utilized the Zymark Rapid,ace; although it was adequate for BZE confirmation, a more efficient procedure was needed to meet a recent increase in workload.
In large measure, the performance of the laboratory is based on reporting turnaround time: the average number of days from sample receipt to report date. Because cocaine is the second most common drug positive in our lab after marijuana, an improvement of even 2 to 3 h in confirmation testing could significantly improve turnaround time for positive specimens.
The Speedisk 48 positive pressure extraction manifold was evaluated as a practical and efficient alternative for extracting the primary cocaine metabolite BZE from urine. The procedure had been used successfully for the analysis of THC (8) , and similar results were expected for BZE. The Speedisk 48 is characterized by greater simplicity and ease of use compared to the current method. This paper presents the results of this validation and describes the usefulness of the procedure in a highvolume workplace drug-testing laboratory.
Experimental

Materials
Extractions utilized a Speedisk 48 positive-pressure extraction manifold (San Pedro, CA) and polymer-based cation-exchange extraction columns (Cerex CLIN II, 35 rag, 3-mL capacity, San Pedro, CA). Methanol, ethyl acetate, ammonium hydroxide, hydrochloric acid, and methylene chloride were ACS grade (Fisher, Pittsburgh, PA). Pentafluoropropionic anhydride (PFPA) and pentafluoropropanol (PFPOH) were purchased from United Chemical Technologies (Bristol, PA).
Control materials were prepared in certified drug-free urine (Roche, Indianapolis, IN) using BZE in methanol purchased
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from Cerilliant Inc. (Austin, TX). Deuterated internal standard stocks BZE-d8 were purchased from Cerilliant, Inc. (Austin, TX). Working solutions of internal standards were prepared in methanol.
Apparatus
All analyses were performed on Agilent (Palo Alto, CA) 6890/5973 GC-MS instruments equipped with autoinjectors and Agilent 15-m HP-5ms columns. The injection port was maintained at 20~ above the initial oven temperature, and oven conditions were maintained isothermally between 225~ and 245~ All injections were split using a split ratio of approximately 15 to 1. The transfer line was maintained at 250~ These conditions resulted in a retention time for the target analyte of approximately 4.0 min. All analyses were performed in selected ion monitoring (SIM) mode monitoring m/z 421,300, 272, 429, and 303. BZE concentrations for specimens and controls were determined by single-point calibration against the 100-ng/mL standard using the rn/z 421/429 ratio. Identifying ratios were m/z 272/421 and 300/421 for the analyte, and m/z 303/429 for the internal standard. Molecular justification of these ions is presented in Figure 1 . The parent ion (M § has a mass-to-charge ratio of 421; the rn/z 272 and 300 ions are formed by cleaving the pentafluoropropyl ester and benzoyl groups, respectively. A full spectrum scan (50 to 500 atomic mass units) obtained from a 0.1 mg/mL BZE control is presented in Figure 2 . The three characteristic ions m/z 272,300, and 421 produced acceptable abundances and were free of spectral interference. 
Method
To 2 mL of urine in a 13 x 100 tube, 0.1 mL of internal standard (BZE-ds, 0.002 mg/mL) and 0.1 mL of 1.0M phosphate buffer (pH 6.0) were added and mixed. Samples were poured into 3-mL SPE columns and placed onto the Speedisk 48; no preconditioning of the columns was required. Positive pressure (2 to 5 psi) was applied to the columns. Subsequently, 1 mL of water was applied to the column followed by 1 mL of 0.1M HC1. The column was dried for 2 rain, and i mL methanol followed by I mL ethyl acetate were applied to the column. The column was again dried for 2 rain at 25 psi. Positive pressure (2 to 5 psi) was applied to the manifold following each reagent addition.
BZE was eluted into automated liquid sampler (ALS) vials by the addition 1.0 mL of methylene chloride/methanol/aminonium hydroxide (70:25:5, v/v). The samples were then evaporated to dryness under a stream of nitrogen using a Zymark TurboVap TM (Hopkinton, MA).
BZE derivatization was based on a two-step reaction with an anhydride and fluorinated alcohol forming a pentafluoropropyl ester from the carboxylic acid (9) . Samples were derivatized by the addition of 0.025 mL pentafluoropropanol (PFPOH) and 0.05 mL of pentafluoropropionic anhydride (PFPA) added directly into the ALS vials. Samples were capped, mixed, and incubated for 10 rain at 60-70~ Samples were removed from the heat block, allowed to cool, and then evaporated to dryness under a stream of nitrogen using a Zymark TurboVap TM (Hopkinton, MA). Samples were then reconstituted with 0.06 mL of ethyl acetate for GC-MS analysis.
Results and Discussion
The procedure permits the rapid analysis of BZE in human urine specimens by SPE with a Speedisk 48 and subsequent quantitation by GC-MS. The method exhibited excellent linearity, precision, limit of quantitation (LOQ), and limit of detection (LOD). Samples are derivatized directly in an ALS vial prior to GC-MS. This process eliminates several sample transfers and improves the overall forensic integrity of the procedure. The procedure also demonstrated no significant difference from previous method results by ANOVA.
Recovery
Drug-free urine samples, spiked at 100 ng/mL BZE, were used in the recovery experiment. Two groups of five samples each were prepared as follows: the first set had internal standard added at the beginning of the extraction (set 1), and the second set had the internal standard added to the ALS vials after elution of the BZE was complete (set 2). An average was taken of the BZE/internal standard area ratio for the two groups of samples. Dividing the averages for sets I and 2 resulted in a measure of recovery. Evaluation of recovery samples indicated that recovery through the column and derivitization averaged 83% with a %CV of 5.2%.
Interference
Chromatographic interference was investigated by assessing the potential for other compounds to coelute with and possess ions that are common to the target analyte or the internal Table I standard. A series of compound mixtures were used in the investigation and included barbiturates, benzodiazepines, tricyclic antidepressants, stimulants, opiates, and common overthe-counter and prescription medications. Control samples containing 100 ng/mL BZE in drug-free urine were spiked with the 75 compounds listed in Table I . The interfering compounds ranged in concentration from 0.2 to 2.5 mg/mL and were representative of therapeutic levels. The interference samples were ana]yzed using the identical BZE procedure in SIM mode. The samples, spiked with the interference mixtures, were analyzed with respect to ion ratios, quantitation, and chromatography. Acceptable chromatography and quantitation were observed, and in the wide range of compounds investigated, none interfered with the identification of BZE or the internal standard. 
Precision, LOD, LOQ, limit of linearity (LOL), and selection of internal standard
Certified drug-free urine was spiked with BZE at seven concentration levels ranging from 12.5 to 20,000 ng/mL in quadruplicate. The LOD was determined to be the lowest concentration for which all replicates produced identity ratios within acceptable limits (20% of calibrator ratios). The LOQ was determined to be the lowest concentration at which the identity ratios were all within acceptable limits, the %CV for the four replicates was within 5% and the mean result was within 10% of the expected concentration. The LOL was determined as the highest concentration at which the ratios were all within acceptable limits, the %CV for the four replicates was within 5% and the mean result was within 10% of the expected concentration. The LOD and LOQ were determined to be 12.5 ng/mL and the Expected values (ng/mL) 25000 assay was linear from 12.5 to 20,000 ng/mL with an r 2 of 0.99932 (F = 38319, df = 27).
Precision
A series of 20 control samples were used to evaluate the precision of the procedure. The 100 ng/mL samples averaged 97.8 ng/mL with a %CV of 4.1. Based on linearity data, excellent correlation and precision were observed over a wide range of concentrations as represented in Figure  3 . Between-run precision was evaluated using a 50-ng/mL control in 143 separate batches prepared by 11 different technicians. The mean response was 48.9 ng/mL with a %CV of 5.0.
Comparative study Figure 3 . Plot of assay linearity. Linear range 12.5 ng/mL to 20,000 ng/mL. Error bars are _+ 1 SD.
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Log ng/ml BZE by old method Figure 4 . Correlation of the complete sample set between the previous and current method. Note that the data are presented as the log of concentration. The two samples that lie off the regression line were high pH samples, and hydrolysis during storage would account for the low results.
Seventy-nine samples previously reported positive for BZE and held in frozen storage for one-year at NDSL Jacksonville (JAX) were used in the comparison study. NDSL San Diego (SD) and NDSL Great Lakes (GL) were provided with 17 split aliquots of the original 79 urine samples for testing. JAX analyzed all the samples. Testing results using the PFPA/PFPOH method were compared against the quantitation obtained previously for the samples. Quantitations using the described method were performed using all controls and acceptance criteria consistent with the previous method. Figure 4 presents the new sample results in comparison to the previous results reported by our laboratory. Notably, two samples exhibited an approximately 50% reduction in concentration compared with the original analysis. The pH for these samples was approximately 9, which may account for the loss of BZE during storage. By a one-way ANOVA, the results were not significantly different between laboratories (F = 0.05309, p = 0.99463). The results correlated well with prior quantitative values obtained for these samples as can be seen in Figure 4 (r 2 = 0.93). Thus, the new assay is reproducible in comparison with previous methods used in our laboratory.
Conclusions References
The analytical characteristics of the described extraction method are excellent. BZE was extracted and derivatized efficiently and accurately. The single-step derivatization technique is a significant improvement that eliminates several label and sample transfers. This and other enhancements save analysis time in comparison with previous methods and improve sample integrity.
The new procedure has been pivotal in improving laboratory efficiency, as measured by a significant reduction in turnaround time. The technician can process a batch of 48 samples and controls within 3 h from setup to injection versus 6 h using the prior method. Since implementation, the average number of days required to report a positive result has been reduced by approximately one day.
